tbuckley/cabot-search huggingface dataset:
Outflow Block Technique Increases Concentration Of Chemotherapeutic Agents in Liver Circulation
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasmaleukapheresis halts graft rejection
Authors: E. Pease
Journal: JAMA (1981)

In 1977, C. J. Cardella and co-workers at the University of Toronto, Canada, reported the use of plasmapheresis in successfully reversing seven renal allograft rejection episodes. In 1979, Jeffrey Kurland, MD, and colleagues at the Cedars-Sinai Medical Center in Los Angeles documented that plasmalymphocytapheresis, a procedure combining plasma exchange and lymphocyte removal, reversed a rejection episode in a patient who had received a kidney from an HLA-identical donor. Recently, at the annual meeting of the American Society of Transplant Surgeons in Chicago, G. Baird Helfrich, MD, director of the Division of Renal Transplantation in the Department of Surgery, Georgetown University Hospital, Washington, DC, presented preliminary data indicating that plasmaleukapheresis (PLP) may help in reversing steroidresistant renal allograft rejection crises. Although having slightly different names, both PLP and plasmalymphocytapheresis denote the same process of exchanging plasma and removing lymphocytes from the peripheral blood. "We recommend that people consider PLP as a
Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients.
Authors: J. M. Perez-Garcia, C. Saura, E. Muñoz, D. Moreno-Fernandez, P. Gomez, M. Vidal, S. Di Cosimo, J. Cortes, J. Baselga, M. Bellet
Journal: Journal of Clinical Oncology (2010)

628 Background: We have previously reported theassociation between PR status and pCR to NACT in breast cancer patients. These data extend and reinforce the results of our first analysis. Methods: From January 2004 to December 2008, 256 consecutive patients were diagnosed with invasive breast cancer and received NACT and breast surgery at our institution. Univariate and multivariate analyses were performed to assess the association between PR status and pCR (defined as no invasive tumor in breast and nodes). Results: Median age was 52.5 years. 84% received anthracycline- and taxanes-based chemotherapy and 46.6% of HER2+ patients were treated with trastuzumab (T). Overall pCR rate was 24.6%. In univariate analysis, high histological grade (HG), estrogen receptor negativity (< 10% nuclei), PR- (< 10% nuclei), HER2+ (Herceptest 3+ or FISH+), high Ki67 (≥ 20%) and T therapy, were significantly associated with higher pCR. In multivariate analysis, only PR status, HER2 and Ki67 maintained statistical significance. In the HER2 - subgroup (n = 192, 16.7% pCR), only HG and Ki67 independently predicted pCR, while in the HER2+ population (n = 60, 51.7% pCR, 67.85% pCR with T-based therapy), PR status and T therapy were the only independent predictive factors of pCR. Conclusions: In our cohort of breast cancer patients treated with NACT, PR status independently predicts pCR in the whole population as well as in the HER2+ patients. PR status should be considered a predictive factor of pCR to NACT, in particular in the HER2+ population. No significant financial relationships to disclose.
SUBCUTANEOUS PHLEBECTASIS OF THE LOWER THORACIC AND UPPER ABDOMINAL REGIONS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Volvulus of the Spleen
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Electrical stimulation of bone growth wins clinical acceptance
Authors: J. Elliott
Journal: JAMA (1980)

The use of electrotherapy to stimulate bone growth in the treatment of nonunited fractures, failed surgical fusions, and congenital pseudoarthroses, long an experimental procedure, has finally come of age. As was evident from the intense interest in the technique at the recent meeting of the American Academy of Orthopaedic Surgery in Atlanta, the proponents of the technique need no longer endure the scorn of colleagues. "To put it bluntly," says Carl T. Brighton, MD, PhD, professor and chairman of the Department of Orthopaedic Surgery at the University of Pennsylvania School of Medicine, Philadelphia, "electricity works. There is a growing interest in this technique. We are just beginning to realize the tremendous promise it holds." Adds C. Andrew L. Bassett, MD, professor of orthopedic surgery at Columbia University's College of Physicians and Surgeons, New York, "It is inevitable that slowly but surely there will be less and less bone grafting for
Correction
Journal: Circulation (2010)

In the article "Endocarditis Secondary to Microsporidia: Giant Vegetation in a Pacemaker User" by Filho et al, which appeared in the April 14, 2009 of the journal (Circulation.2009;119;e386 -e388), several errors have been corrected.The legend for Figure 1 should read, "Twelve-lead surface ECG obtained in the operating room with the pacemaker programmed to asynchronous mode."On page e386, first paragraph, line 11, where it is written "ECG showed a normally functioning pacemaker" it should be "ECG showed a normally functioning pacemaker programmed to asynchronous mode just before surgery."Also on page e386, second paragraph, line 12, where it says "persistent bacteremia," it should read "persistent fever and chills," Again on page e386, second paragraph, line 14 where it says "without signs of endocarditis," it should be "not adherent to the atrium wall or the tricuspid valve."On page e387, in the legend to Figure 3, third line, where it is written "that did not compromise the tricuspid valve," it should read "that did not adhere to the tricuspid valve."The online version of the article has been corrected.
Postmortem on Winter Olymphics medical care
Authors: P. Gunby
Journal: JAMA (1980)

Tomorrow the summer Olympic Games begin in the Union of Soviet Socialist Republics. The United States, Japan, and some other key countries will not send participants. Meanwhile, back in the United States, Olympic physicians are compiling their reports on the medical experience at the Winter Games in Lake Placid, NY. George G. Hart, MD, a Lake Placid-born family practitioner who was chairman of medical arrangements for that community's Olympic Organizing Committee, says a total of 2,537 "treatments" of athletes, spectators, and support personnel was recorded. However, says Hart, those "treatments" require some sorting out. For example, the computer would have him believe that 14 fractured calcanei were treated during the games, but he has not seen that many broken heelbones in his entire practice. As it turns out, one person fractured a calcaneus and had 14 whirlpool treatments. Hart, his vice-chairman Edward G. Hixson, MD, of Saranac Lake, NY, and
英夫利昔单抗用于银屑病患者及其引起严重感染的 风险
Authors: Z.Z.N. Yiu, D.M. Ashcroft, I. Evans, K. McElhone, M. Lunt, C.H. Smith, S. Walton, R. Murphy, N.J. Reynolds, A.D. Ormerod, C.E.M. Griffiths, R.B. Warren
Journal: British Journal of Dermatology (2019)
Hypertension: Treatment Successes and Failures
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Education Programs Sponsored by Government Agencies
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Journal of Pathology, New York
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM)
Authors: M Coomans, L Dirven, A Bottomley, M van den Bent, J Sloan, R Stupp, M Weller, J C Reijneveld, M Taphoorn, N Aaronson, B G Baumert, A A Brandes, O Chinot, C Coens, T Gorlia, U Herrlinger, F Keime-Guibert, A Malmström, F Martinelli, A Talacchi, W Wick
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The impact of treatment on both the quality and the quantity of life, i.e. the ‘net clinical benefit’, should be considered to inform glioma patients and facilitate shared decision making. We applied two methods (i.e. Quality Adjusted Effect Sizes (QASES) and Joint Modelling (JM)) that combine survival and health-related quality of life (HRQoL) data into one outcome, to gain insight in the net clinical benefit of a treatment strategy. In addition, we assessed if both methods result in similar interpretations. MATERIAL AND METHODS We calculated the net clinical benefit in one randomized controlled trial, EORTC 26951 comparing radiotherapy (RT) + PCV chemotherapy versus RT alone, as a proof of concept for other trials. With the QASES method, effect sizes for differences in survival and HRQoL between treatment arms were calculated. Next, the combined effect size can be determined by weighing the emphasis put on survival or HRQoL (e.g. survival more important). JM allows simultaneous modeling of a longitudinal outcome (HRQoL), and a time-to event outcome (survival). HRQoL scales/items that were selected for primary analysis in the main study were also selected for this analysis: fatigue, global health, social functioning, communication deficit, seizures, physical functioning, and nausea/vomiting. RESULTS 288/386 patients completed baseline HRQoL forms and were included in the analysis. Overall survival (OS) was significantly longer with combined treatment (difference of 10.8 months). In contrast, the percentage of patients who experienced a clinically relevant deterioration (≥10 points) in nausea/vomiting, fatigue, social functioning and global health up to one year after treatment compared to baseline was larger in the RT+PCV arm. The QASES corresponded to a reduction in the median OS difference from 10.8 months to 6.8 months when adjusted for the HRQoL scales/items, when given equal weights to OS and HRQoL. JM analyses resulted in a theoretical loss of treatment effect in OS of 2–6% when adjusting for HRQoL. CONCLUSION Both methods showed that adjusting for the impact of treatment on a relevant HRQoL parameter reduced the survival benefit in the experimental treatment arm compared to standard treatment arm. Applying these methods may facilitate communicating the impact of treatment to patients in clinical practice.
Malnutrition and hunger in the United States. Report of the Council on Foods and Nutrition to the AMA board of Trustees
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response to Scientific journals are 'faith based': is there a science behind peer review?
Authors: S. Schroter
Journal: Journal of the Royal Society of Medicine (2007)

It is clear the authors are ignorant of the role, training and history of my profession; otherwise they would have known better than to use the surgical role as their example.To appreciate the folly of this example, one must understand that for many years the theatre nursing hierarchy sought to deny ODPs the opportunity to practice in the surgical role-claiming this 'a purely nursing function'.My profession was then predominantly associated with providing care as part of the anaesthetic team, where patients are initially conscious, often fearful and requiring both psychological and physiological support.As far back as the 1970s our syllabus incorporated patient care (e.g.'Respect the dignity and rights of the patient; Principles of ethics and etiquette; Psychological reaction of patients to surgery and the theatre environment').These were introduced early and developed throughout the course.Today's qualification has developed these themes into the modern era, with emphasis on the assessment, planning and evaluation of care.Caring is not genetically implanted into nurses, but taught to all professions with caring responsibilities.The notion that ODPs are 'expropriating nurses' knowledge and skills' is laughable.We had the first nationally organized course in operating department practice in 1951.In 1989 Bevan 2 noted 'only 13.8% of nurses working in theatre had received post-registration training in operating department and/or anaesthetic nursing.'Throughout the 1990s the NVQ in Operating Department Practice, the ODP's primary qualification, was taken by many perioperative nurses as their preferred postgraduate qualification.
Folate Deficiency and Pregnancy
Authors: E. J. H.
Journal: Annals of Internal Medicine (1967)

Editorial Notes1 January 1967Folate Deficiency and PregnancyE. J. H.E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-1-235 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe recommendation of Lawrence and Klipstein, in their paper in this issue of the ANNALS, that folic acid be given routinely to all pregnant women is supported by data reported recently by Lowenstein, Cantlie, Ramos, and Brunton (1) from Montreal. Of nonanemic pregnant women treated from the twenty-ninth week of gestation or earlier with vitamin-iron preparation lacking folic acid and vitamin B12, 26% developed megaloblastic marrows and 50%, low serum folates by the thirty-eighth week. Of women in the same study given folic acid and vitamin B12in addition, only 3% developed megaloblastic marrows, and their serum folates rose to...References1. LOWENSTEINCANTLIERAMOSBRUNTON LGOL: The incidence and prevention of folate deficiency in a pregnant clinic population. Canad. Med. Ass. J. 95: 797, 1966. MedlineGoogle Scholar2. ABRAMOWICZKASS MEH: Pathogenesis and prognosis of prematurity. New Eng. J. Med. 275: 938, 1966. CrossrefMedlineGoogle Scholar3. WILSONJONES COTE: American Drug Index 1966. J. B. Lippincott Co., Philadelphia and Montreal, 1966. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1967Volume 66, Issue 1Page: 235-236KeywordsBone marrowFolate deficiencyFolic acidPregnancyResearch design ePublished: 1 December 2008 Issue Published: 1 January 1967 PDF downloadLoading ...
Options for multiple sclerosis therapy
Authors: P. Cotton
Journal: JAMA (1994)

TWO NEW drugs, apparently acting in different ways, may soon provide clinical options in treating multiple sclerosis. Only a year ago there were no effective agents on the market to delay the course of autoimmune nerve demyelination. The Food and Drug Administration late in 1993 approved interferon beta-1b (Betaseron, Chiron Corp, Emeryville, Calif), based on data showing a significantly reduced relapse rate. Now two other agents appear not only to reduce the remission rate but also to slow disease progression and delay the onset of physical disability, according to reports at the annual meeting of the American Neurological Association, held in San Francisco, Calif. It is "very significant" that the drugs showed an effect on the rate of progression, says Abe Eastwood, PhD, director of research grant programs at the National Multiple Sclerosis Society, New York, NY. "There has never been a drug that's had" such an effect. While direct